Drug, bio-affecting and body treating compositions inventions 03/07

20070071670 - Diagnostic imaging agents with mmp inhibitory activity: The present invention relates to the field of diagnostic imaging. Specifically, the invention relates to the diagnostic imaging of diseases where specific matrix metalloproteinases are known to be involved. One embodiment of the invention is a compound having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the... Agent: Ge Healthcare, Inc.

20070071671 - Process for producing radioactive-fluorine-labeled compound: An on-column process by which various radioactive-fluorine-labeled compounds can be obtained in a high yield. The process comprises a step in which [18O] water containing [18F] fluoride ions is introduced into a column packed with an anion-exchange resin for labeled-compound synthesis to collect the [18F] fluoride ions, a step in... Agent: Sughrue Mion, PLLC

20070071673 - Trifunctional reagent for conjugation to a biomolecule: A reagent for conjugation to a biomolecule, wherein the reagent is a single molecule with at least three functional parts and has schematic structure (I): a) wherein a trifunctional cross-linking moiety is coupled to b) an affinity ligand via a linker 1, said affinity ligand being capable of binding with... Agent: Swanson & Bratschun L.L.C.

20070071672 - Use of metal tricarbonyl complexes as radiotherapeutic chemotoxic agents: The invention relates to the use of metal tricarbonyl compounds of the general formula [M(CO),L,]′, wherein M is rhenium or technetium or an isotope thereof and L is a ligand, for the preparation of a medicament for the treatment of cancer that is both radiotherapeutic and chemotoxic when a radioactive... Agent: Jerad Seurer Mallinckrodt Inc.

20070071675 - Dual variable domain immunoglobulin and uses thereof: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.... Agent: Abbott Bioresearch

20070071676 - Methods and therapies for treating inflammatory conditions with exposed collagen: Compositions and methods for treating and imaging vulnerable plaque and other inflammatory conditions in a patient rely on the delivery of conversion electron-emitting sources and other radionuclides to regions of exposed collagen in the vasculature or other body lumens. The conversion electron-emitting sources or other radionuclides are coupled to a... Agent: Townsend And Townsend And Crew, LLP

20070071674 - Polynucleotides encoding novel isoforms of igsf9: Human IGSF9 and LIV-1 polypeptides and DNA (RNA) encoding such polypeptides are disclosed. The disclosed polypeptides and/or polynucleotide are particularly useful generating antibodies, both modified and native, which bind IGSF9 or LIV-1. Also disclosed are pharmaceutical compositions and vaccines comprising the antibodies, polypeptides and polynucleotides of the invention. Also disclosed... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20070071678 - Electrical initiation system: An apparatus and method of using electrically initiated primer systems that rely on vaporizing a thin metallic film which is either coated on a non-conductive insulator component or is a malleable thin film or strip secured to the inner surface of a primer cup assembly to ignite an environmentally safe... Agent: Navairwd Counsel Group

20070071677 - Non-toxic membrane-translocating peptides: Compositions for transport across a biological membrane include a membrane-translocating LMWP peptide and a cargo molecule. Methods for transporting a cargo molecule across a biological membrane are also described.... Agent: Mayer, Brown, Rowe & Maw LLP

20070071680 - Methods and compositions for preparing consumables with optical shifting properties: Ingestible compositions comprising a chromic change agent together with methods of making and using them are provided. The chromic change agent alternatively may be associated with the ingestible, such as a packaging material for the ingestible. In response to a triggering event, physical or chemical, the chromic change agent changes... Agent: Bozicevic, Field & Francis LLP

20070071679 - Methylamine risks and treatment of hyperactivity, depression, and alcoholism with epinephrine-n-quinolines: Results of animal experiments proving a relationship between ontogenetically early sleep-wake behaviour and neurobehavioural disorders during later life indicate examination of ontogenetically early sleep-wake behaviour in human beings. With drugs with N-adrenaline moiety and with drugs with PNMT-inhibiting activity, in addition with effects on adrenergic beta and alpha-1 receptors, and... Agent: Ilkka Tapio Hilakivi

20070071681 - Apparatus and method for computer modeling type 1 diabetes: The invention encompasses novel methods for developing a computer model of type 1 diabetes in a mammal. In particular, the models can include representations of biological processes associated with a pancreatic lymph node and one or more pancreatic islets. Alternatively, the models can include representations of biological processes associated with... Agent: Entelos, Inc. C/o Foley & Lardner LLP

20070071682 - Methods for testing vaccine candidates against bacterial infection in rodents: Methods and a rodent model to test the effectiveness of vaccine candidates against bacteria, e.g., Staphylococcus aureus by systemically immunizing a rodent, particularly a cotton rat, with a vaccine candidate, intranasally challenging the cotton rat with the selected bacteria, and detecting a response with respect to an immune response, nasal... Agent: Lahive & Cockfield, LLP

20070071683 - Ultrasonic concentration of carrier particles: Methods, compositions, and apparatus for localized delivery of compounds are provided. In certain embodiments, acoustic streaming force is used to direct carrier particles to a target site, mediate particle internalization, and release associate compounds. Ultrasound radiation is preferred as the source for the acoustic streaming force. Also encompassed are embodiments... Agent: Fenwick & West LLP

20070071685 - Gas-filled microvesicle assembly for contrast imaging: Assembly comprising a gas-filled microvesicle and a structural entity which is capable to associate through an electrostatic interaction to the outer surface of said microvesicle (microvesicle associated component—MAC), thereby modifying the physico-chemical properties thereof. Said MAC may optionally comprise a targeting ligand, a bioactive agent, a diagnostic agent or any... Agent: Bracco Research Usa Inc.

20070071684 - Process for the preparation of surface coatings and films: A method of coating the surface of a substrate which comprises the steps of: i) contacting the surface with a polymerisable mixture comprising one or more polymerisable components and containing suspended droplets of a biliquid foam or of a high internal oil phase emulsion, the said droplets being stabilised by... Agent: Dykema Gossett PLLC

20070071687 - Intranasal benzodiazepine compositions: A pharmaceutical composition for intranasal administration to a mammal. The pharmaceutical composition comprises an effective amount of a benzodiazepine or pharmaceutically acceptable salt thereof; and a nasal carrier. In some embodiments, the pharmaceutical composition when administered intranasally produces a rapid physiological response. Pharmaceutical compositions may also include at least one... Agent: Mayer, Brown, Rowe & Maw LLP

20070071686 - Liquid preparation containing tobramycin: The application describes a sterile aqueous inhalation solution containing the active agent tobramycin. The preparation has a high content of active agent (about 80 to 120 mg/ml of tobramycin) and contains an acidic adjuvant, but contains only a low concentration of sodium chloride (at most about 2 mg/ml). It can... Agent: Edwards & Angell, LLP

20070071688 - Pharmaceutical compositions for transdermal administration of anti-inflammatory agents: A pharmaceutical composition for transdermal administration comprising a polymeric release matrix capable of forming a supple film after drying, selected among cellulose polymers or copolymers; an active principle selected among the group of non-steroid anti-inflammatory agents comprising at least one carboxylic or metal carboxylate group; a transcutaneous absorption promoter; water;... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070071689 - Advantageous combination for inhalation of nacystelyn and bronchodilators: pharmaceutical combination or composition for inhalation a fixed combination (A) L-lysine N-acetylcysteinate and (B) a bronchodilator agent for simultaneous, sequential or separate administration by inhalation in the treatment of an inflammatory or obstructive respiratory disease.... Agent: Lowe Hauptman Berner, LLP

20070071692 - Aerosol powder formulation: This invention relates to dry power aerosol formulations for use with a dry powder inhaler, the formulation comprising the PDE 4 inhibitor N-cyclopropyl-1-[3-(1-oxido-3-pyridinylethynyl)phenyl]-1,4-dihydro[1,8]naphthyridin-4-one-3-carboxamide:... Agent: Merck And Co., Inc

20070071691 - Composition: Dry powder pharmaceutical compositions having improved storage stability, dry powder inhalers comprising the same and their use in the treatment of respiratory disorders by inhalation.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070071690 - Dry powder formulations: A dry powder suitable for inhalation in a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20070071694 - Composition for oral cavity: The invention relates a composition for oral cavity for preventing adhesion of Porphyromonas gingivalis as periodontopathic bacterium to oral tissue. The invention also relates to a composition for oral cavity containing a peptide in which arginine and histidine bind alternately. Preferably, the invention includes a composition for oral cavity including... Agent: Hogan & Hartson LLPIPGroup, Columbia Square

20070071693 - Therapeutic agent and therapeutic method for periodontal diseases and pulpal diseases: The objects of the present invention are: to provide a therapeutic agent and a therapeutic method for periodontal diseases and pulpal diseases, a transplant for periodontal tissue regeneration, and a method for regenerating the periodontal tissue. According to the present invention, there are provided therapeutic agents for periodontal diseases and... Agent: Drinker Biddle & Reath (dc)

20070071696 - Dual phase whitening dentifrice: A dual phase whitening oral care composition comprising a first phase comprising a bound peroxide in a substantially anhydrous carrier and a second phase comprising an abrasive and a tartar control system in an orally acceptably carrier. Methods of whitening a tooth surface are also provided.... Agent: Colgate-palmolive Company

20070071695 - Single phase whitening dentifrice: The invention provides a single phase whitening dentifrice that includes (i) a whitening agent selected from the group consisting of hydrogen peroxide, a bound peroxide and a solid peroxide (ii) an abrasive and (iii) a substantially anhydrous orally acceptable carrier, for example, polyethylene glycol. The bound peroxide may be hydrogen... Agent: Colgate-palmolive Company

20070071699 - Benzylidene-1,3-thiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting their depigmentation and/or whitening: are useful active agents for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or preventing and/or limiting the depigmentation and/or bleaching thereof, particularly of human head hair, beard hair, moustache hair, eyelashes and eyebrows, and advantageously are active agents for preventing and/or limiting the canities of human keratin... Agent: Buchanan, Ingersoll & Rooney PC

20070071697 - Therapeutic soap product with uv protection: The present invention concerns a cleansing composition that imparts sun protection for the skin through normal daily use during bathing, washing, or cleaning of the body or face. The cleansing composition of the present invention comprises a unique combination of ingredients that provides therapeutic and restorative properties for the skin.... Agent: John J. Yim, Esq.

20070071698 - Therapeutic soap product with uv protection: The present invention concerns a cleansing composition that imparts sun protection for the skin through normal daily use during bathing, washing, or cleaning of the body or face. The cleansing composition of the present invention comprises a unique combination of ingredients that provides therapeutic and restorative properties for the skin.... Agent: John J. Yim, Esq.

20070071700 - Cosmetic compositions containing silicone/organic copolymers: A cosmetic composition comprising at least one lipophilic liquid alkoxylated film forming polymer comprised of siloxane portions and urethane portions.... Agent: Julie Blackburn Revlon Consumer Products Corporation

20070071701 - Antiperspirant actives and compositions: Polyol-sprayed particulate antiperspirant actives, methods of manufacture thereof, and compositions comprising polyolsprayed particulate antiperspirant activities and carrier materials are described.... Agent: Unilever Intellectual Property Group

20070071703 - High efficiency master gels for thickening oil based compositions: The composition, preparation and use of a thickening system or master gel for oil based compositions, especially cosmetic compositions is described. These highly efficient master gels include: i) greater than about 10% to about 40% of an organoclay, ii) from about 70% to less than about 90% of a carrier... Agent: Michael P. Aronson Mp&g Aronson Inc.

20070071704 - Silicone-in-water emulsion compositions containing retinoids: The present invention relates to a composition containing a retinoid wherein the composition is a silicone-in-water emulsion, and the use thereof.... Agent: Philip S. Johnson Johnson & Johnson

20070071706 - Lipodissolving dermatological topical preparation: A dermatological topical preparation such as a cream, a lotion, an emulsion, a paste, an ointment and the likes where a lipo-dissolving emulsifier such as a biliary compound is transdermally delivered through the superficial layers of the skin into the subcutaneous adipose tissue with the use of skin permeability enhancers.... Agent: Filiberto Zadini

20070071705 - Topical anti-microbial compositions: Topical anti-microbial compositions, and more particularly anti-bacterial and anti-fungal compositions, comprising a therapeutically effective amount of an anti-microbial agent, a starch, a hydroalcoholic solvent, and a volatile silicone compound having a viscosity of about 0.1 to about 50 centistokes. These compositions are capable of temporarily or permanently reducing, inhibiting, treating,... Agent: Nath & Associates

20070071707 - Composition and method of transmitting ultrasonic and electrical impulses using a physiologically compatible conductive agent: The present invention provides a physiologically compatible conductive agent comprising (a) a long chain water-soluble ionic polymeric thickening agent selected from the group consisting of a copolymer of methyl vinyl ether and maleic anhydride, carboxy polymethylene polymer, and mixtures thereof, present in an amount from about 0.05 wt. % to... Agent: Richard R. Muccino

20070071708 - Anhydrous hair compositions comprising a phosphate ester: A composition and process for treating a keratinous substrate involving contacting the keratinous substrate with a composition containing: (a) at least one alkoxylated alkyl phosphate ester; (b) at least one ester oil component; and (c) optionally, at least one non-ester oil component.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070071709 - Hair cosmetic composition: (B) a C8-30 aliphatic alcohol, and (C) toluenesulfonic acid or salt thereof. The hair cosmetic composition is excellent in the effect of restoring the flyaway or waved hair, which has appeared as a result of accumulation of damage due to hair coloring or the like, to its former state before... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070071702 - Use of a polyguanidine compound for treating or shaping the hair, especially for straightening or permanent-waving it: The present invention relates to the use of a cosmetic composition containing compounds derived from polyguanidines or physiologically acceptable salts thereof for the protection of keratin fibres during permanent-shaping treatments or hair-straightening operations. The invention also relates to a cosmetic treatment process for permanently shaping or straightening keratin fibres, such... Agent: Steptoe & Johnson LLP

20070071710 - Extract of vanilla planifolia: The invention relates to an extract of vanilla originating from at least one species of vanilla plant (family Orchidaceae), to the method for obtaining it, to a cosmetic or dermatological composition containing it, and to its use as a polyfunctional active agent in a cosmetic or dermatological composition, for the... Agent: Hunton & Williams LLP Intellectual Property Department

20070071711 - Formulations for topical delivery of bioactive substances and methods for their use: The invention relates to topical delivery of bioactive agents. More particularly, the invention relates to anhydrous formulations for percutaneous absorption. The invention provides formulations that allow efficient topical delivery of high concentrations of bioactive substances for percutaneous absorption. The formulations according to the invention are generally non-irritating to the skin.... Agent: Keown & Associates

20070071713 - Functionalized dendritic polymers for the capture and neutralization of biological and chemical agents: The present invention describes compositions and methods for trapping/capturing and/or destroying dangerous substances such as chemical and biological warfare agents. The present invention relates to dendritic polymers, specifically, to quaternary ammonium functionalized dendritic polymers and N-Halamine functionalized dendritic polymers. Such dendrimers are useful for the capture and neutralization of biological... Agent: Pepper Hamilton LLP 50th Floor

20070071715 - Methods and compositions for phosphate binding: The present invention provides improved methods and compositions for therapeutically controlling and/or reducing serum phosphate levels in animals and mammalian patients. The methods comprise administering to the patient an amount of a dendrimer composition effective to prevent absorption of substantial amounts of phosphate from the patient's GI tract. In a... Agent: Quarles & Brady LLP

20070071712 - Polymer network compositions and associated methods: Biomimetic polymer networks comprising a heteropolymer network having a cavity, the cavity having a selective affinity for a moiety, methods for making biomimetic polymer networks, and methods for using biomimetic polymer networks.... Agent: Baker Botts L.L.P. Patent Department

20070071714 - Stem cell factor: Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed.... Agent: Marshall, Gerstein & Borun LLP

20070071716 - Compositions and methods for healthy pregnancy: Compositions, kits and methods for the prevention of, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure during assisted reproduction are provided. The compositions, kits and methods provide an effective amount of granulocyte colony stimulating factor to prevent, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure of... Agent: Bell, Boyd, & Lloyd LLP

20070071717 - Treatment of b cells with il-21 and b cell activators induces granzyme b production: The present invention involves the combined use of IL-21 and TLR agonists such as CpG oligonucleotides in the treatment of B cell cancers and B cell-related immune pathologies such as autoimmune diseases. In addition, it is demonstrated that human B cells produce and secrete varying amounts of Granzyme B in... Agent: Fulbright & Jaworski L.L.P.

20070071718 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20070071719 - Compositions and methods for regulation of tumor necrosis factor-alpha: The present invention relates to compositions and methods relating to an interleukin18-inducible cytokine termed tumor necrosis factor-alpha inducing factor (TAIF) or interleukin-32 (IL-32). In particular, the present invention provides compositions and methods for treating autoimmune diseases and cancer, in part by regulation of tumor necrosis factor-alpha expression.... Agent: Medlen & Carroll, LLP

20070071720 - Method of treating hepatitis b viral infection: The present invention provides the use of PEG-IFN-α conjugates in association with ribavirin for the treatment of chronic hepatitis B infections. The present invention also provides a method for treating chronic hepatitis B infections in patients in need of such treating comprising administering an amount of PEG-IFN-α conjugate in association... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070071721 - Methods for treating viral infection using il-28 and il-29: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof... Agent: Zymogenetics, Inc. Intellectual Property Department

20070071723 - In vivo enhancement of immune system recognition of neoplasms following treatment with an oncolytic virus or gene therapy vector: This invention provides novel methods of treating or alleviating neoplasms and enhancing the efficacy of oncolytic viruses by administering an oncolytic virus to a mammal suffering from a neoplasm and subsequently administering an immunostimulant. The invention also provides methods of increasing immunorecognition of neoplastic cells.... Agent: Fish & Richardson P.C.

20070071724 - Methods for increasing learning and memory in amyloid-beta-related neurodegenerative disorders by increasing uch-l1 activity and methods for identifying enhancers of uch-l1 activity: The invention is directed to methods for increasing learning and memory in a subject with a neuropathological condition, specifically a condition related to elevated beta-amyloid deposition, the method comprising administering to the subject an effective amount of a compound capable of increasing the activity of Uch-L1. The invention is also... Agent: Wilmerhale/columbia University

20070071725 - Nitric oxide synthase gene transfer: This invention relates to to gene transfer, specifically, provided herein are methods, vectors and compositions for the transfer of nNOS gene affecting overexpression of nNOS in sympathetic and parasympathetic nervous system and its subsequent use in the treatment of related pathologies.... Agent: Pearl Cohen Zedek, LLP Pearl Cohen Zedek Latzer, LLP

20070071722 - Nucleotide vaccine composition: The present invention refers to a novel combination of nucleotide and cellular vaccine composition and pharmaceutical composition and use thereof for treating and/or preventing diseases, including infectious diseases, cancer, autoimmune diseases, allergy, diabetes and blood disorders. The vaccine composition comprises a nucleotide sequence encoding an antigenic molecule and gene-modified antigen-presenting... Agent: Dinsmore & Shohl, LLP

20070071726 - Recombinant viral-based malaria vaccines: The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such as infections by P. falciparum or P. yoelii. Novel codon-optimized circumsporozoite genes are... Agent: Trask Britt

20070071734 - Arpe-19 as platform cell line for encapsulated cell-based delivery: ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice;... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070071735 - Method and apparatus for installation of dental implant: An organ derived from genetic material is inserted in a patient's body. Genetic material is inserted at a selected site in the body to grow an organ.... Agent: Gerald K. White, Esq. Gerald K. White & Associates, P.C.

20070071736 - Method and apparatus for installation of dental implant: An organ derived from genetic material is inserted in a patient's body. Genetic material is inserted at a selected site in the body to grow an organ.... Agent: Gerald K. White, Esq. Gerald K. White & Associates, P.C.

20070071737 - Live bacterium preparation containing lactic acid bacterium as active ingredient and food containing lactic acid bacterium: Disclosed is a live bacterium preparation or food containing a lactic acid bacterium comprising a lactic acid bacterium, Lactobacillus salivarius, as an active ingredient. There is provided a live bacterium preparation and food containing a lactic acid bacterium that can prevent onset, recurrence and exacerbation of periodontal disease and/or dental... Agent: Bacon & Thomas, PLLC

20070071738 - Propionibacterium p-63 for use in direct fed microbials for animal feeds: A ruminant direct fed microbial composition of matter comprising an acidosis inhibiting effective amount of Propionibacterium P-63 is provided. Also disclosed is a process for reducing acidosis in ruminants or scours in swine by administration of the bacterium to the ruminant or swine. The microbial composition may be administered by... Agent: Fellers Snider Blankenship Bailey & Tippens

20070071739 - Treatment of bipolar disorder utilizing anti-fungal compositions: A method for treatment or prophylaxis of a bipolar disorder disease state, by administration of an anti-fungal composition that includes at least one of the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium.... Agent: Intellectual Property / Technology Law

20070071728 - Biomimetic nanocomposite: A biomimetic nanocomposite including hydroxyapatite nanocrystals, gelatin, and polymer, wherein the biomimetic nanocomposite is crosslinked is described. Also described is a process for making the nanocomposite. Additionally, a method for using the nanocomposite, and articles formed from the nanocomposite are also described.... Agent: Fish & Richardson P.C.

20070071729 - Dermal fillers for biomedical applications in mammals and methods of using the same: A method of tissue augmentation in mammals comprising implanting or injecting into the tissue of a mammal elastic material derived from solar elastosis or other sun-damaged sites in humans is disclosed. The method further comprises injecting into the tissue of a mammal, alone, or in combination with the solar elastosis,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070071727 - Melanocytes in therapy of neurodegenerative diseases: In vitro cultivation method for producing human melanocytes which are capable of melanin and/or L-dopa synthesis, and to various uses of said melanocyte(s). In one preferred aspect, said melanocyte(s) are used in an autologous implantation method in a patient suffering from a neurodegenerative disease, e.g. Parkinson's disease. In another aspect,... Agent: Rissman Jobse Hendricks & Oliverio, LLP

20070071731 - Promotion of neurogenesis of endogenous and transplanted human neural stem cells: Disclosed herein are methods and materials for promoting neurogenesis of endogenous and transplanted stem cells. Specifically exemplified herein are methods that comprise transplanting neural stem cells in conjunction with a regimen of (+)phenserine treatment.... Agent: Beusse Wolter Sanks Mora & Maire

20070071732 - Secretory cell-containing macrobeads comprising seakem gold agarose, and uses thereof: The invention describes the manufacture and use of secretory cell containing bead structures that are coated with agarose. The beads, which are preferably 4 mm-12 mm in diameter, and which preferably contain islets, are made of a particular agarose, i.e., Seakem Gold agarose.... Agent: Fulbright & Jaworski, LLP

20070071730 - Stem cells of the islets of langerhans and their use in treating diabetes mellitus: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker... Agent: Palmer & Dodge, LLP Kathleen M. Williams

20070071733 - Synthetic substrate for tissue formation: The invention relates to a substrate on which to grow synthetic cartilage, a method for preparing the substrate, a synthetic cartilage patch comprising the substrate, and methods of using the synthetic cartilage patch.... Agent: Howson And Howson

20070071740 - Purified amniotic membrane compositions and methods of use: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from... Agent: Wilson Sonsini Goodrich & Rosati

20070071741 - Ocl-2a3 compositions and uses thereof: This invention relates to osteoclast-specific genes and proteins. Specifically, the invention relates to OCL-2A3 or Atp6v0d2, the gene encoding it and uses thereof in methods and treatment of bone disorders.... Agent: Pearl Cohen Zedek, LLP Pearl Cohen Zedek Latzer, LLP

20070071742 - Humanized antibodies: Humanized antibodies that bind ICAM-1 are provided. Antibodies include those selected from: SEQ ID NO:1 and 3 (HumA); SEQ ID NO:5 and 7 (HumB); SEQ ID NO:9 and 11 (HumC); SEQ ID NO:13 and 15 (HumD); SEQ ID NO:17 and 19 (HumE); SEQ ID NO:21 and 23 (HumF); SEQ ID... Agent: Mr. Robert M. Jaffe

20070071743 - Novel human cell surface protein with immunoglobulin folds, bgs-19: The present invention provides novel polynucleotides encoding BGS-19 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying the novel BGS-19 polypeptides to the diagnosis, treatment, and/or prevention... Agent: Louis J. Wille Bristol-myers Squibb Company

20070071744 - Agents which bind to epitopes of glycoprotein vi: The present invention provides anti-thrombotic agents, methods for screening for said anti-thrombotics agents and methods of treating thrombotic and other cardiovascular disorders.... Agent: Klarquist Sparkman, LLP

20070071746 - C/clp antagonists and methods of use thereof: The invention relates to the novel discovery that antagonizing a C/CLP can be useful for the treatment of diseases associated with the upregulation of one or more C/CLP such as Th2-driven and/or IL-13 mediated inflammatory diseases. Accordingly the present invention provides C/CLP antagonists and also provides compositions and methods for... Agent: Johnathan Klein-evans

20070071745 - Modified antigen binding molecules with altered cell signaling activity: The present invention relates to modified antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies or fragments, including chimeric, primatized or humanized antibodies or fragments, having altered ability to mediate cell signaling activity by a target antigen, and/or altered ability to mediate cross-linking of... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070071748 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20070071749 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20070071747 - Use of tnfalpha inhibitor for treatment of erosive polyarthritis: The invention describes methods of treating erosive polyarthritis comprising administering a TNFα antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNFα antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.... Agent: Lahive & Cockfield, LLP

20070071751 - Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof: An isolated polynucleotide at least 60% homologous to SEQ ID NO: 1, 3, 5 or 18 encoding a SARP polypeptide; vectors comprising a polynucleotide sequence encoding at least 11 consecutive amino acids of αSARP polypeptide; a host cell transformed with an isolated polynucleotide or vector; antibodies specific for SARP and... Agent: Sheridan Ross PC

20070071750 - Human antibody variants that specifically recognize the toxin cn2 from centruroides noxius scorpion venom: The present invention is directed to recombinant human antibodies specific for Cn2 toxin from C. noxius scorpion venom. The antibodies are able to recognize the toxin and preferably neutralize it as well as the whole venom of C. noxius scorpion. This invention is also directed to a human non-immune phage... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070071752 - Sphingosine kinase enzyme: The present invention relates generally to novel protein molecules and to derivatives, analogues, chemical equivalents and mimetics thereof capable of modulating cellular activity and, in particular, modulating cellular activity via the modulation of signal transduction. More particularly, the present invention relates to human sphingosine kinase and to derivatives, analogues, chemical... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070071759 - Antibody-immune cell ligand fusion protein for cancer therapy: Compositions for treatment of cancer comprising chimeric fusion molecules that bind to an antigen on a pathogenic cell and to an immune cell. The molecules redirect the immune cells to a pathogenic cell. The purified fusion proteins demonstrated ability to bind antigen on the surface of tumor cells and cell... Agent: Akerman Senterfitt

20070071758 - Ceacam1 based cancer therapy and diagnosis: The invention relates to methods and compositions for the treatment and diagnosis of cancers. At least one aspect of the present invention relates to methods and compositions for enhancing the efficacy of tumor-infiltrating lymphocyte (TIL) therapy in the treatment of cancer by negatively modulating the activity of the CEACAM1 protein.... Agent: Mcandrews Held & Malloy, Ltd

20070071762 - Comprehensive diagnostic testing procedures for personalized anticancer chemotherapy (pac): The present invention provides methods of assessing and selecting treatment modalities for cancer.... Agent: Connolly Bove Lodge & Hutz LLP

20070071756 - Delivery of an agent to ameliorate inflammation: A method delivering an anti-vascular endothelial growth factor (VEGF) agent to ameliorate inflammation at a site in the body that may be the eye, a joint, the brain, etc. or to reduce corneal neovascularization. In one embodiment, one or more other agents, such as non-steroidal anti-inflammatory agents, steroids, etc., may... Agent: Wood, Herron & Evans, LLP

20070071753 - Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 85 (gpr85): The invention provides a human GPR85 which is associated with the cardiovascular disorders, hematological disorders, inflammatory diseases, metabolic diseases, neurological disorders, urological disorders, respiratory diseases, cancer disorders and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, hematological... Agent: Banner & Witcoff

20070071761 - Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody: The present invention provides a method for enhancing the efficacy of chemotherapeutic agents for therapy of cancer including tumors and other angiogenesis-associated diseases such as rheumatoid arthritis. The method comprises the steps of administering to an individual in need of treatment, a combination of an anti-endoglin antibody and a chemotherapeutic... Agent: Hodgson Russ LLP

20070071754 - Method to ameliorate inflammation: Administering to a patient a concentration of at least one anti-inflammatory agent and bevacizumab at a concentration sufficient to reduce fluid leakage from new vessels associated with angiogenesis.... Agent: Wood, Herron & Evans, LLP

20070071760 - Methods for treating b-cell malignancies using a taci-ig fusion molecule: The present invention provides methods and compositions for treatment of B-cell malignancies, including non-Hodgkin's lymphoma, comprising administering to a patient in need of the treatment a TACI-Ig fusion molecule in amount sufficient to suppress proliferation-inducing functions of BlyS and APRIL.... Agent: Howrey LLP

20070071757 - Novel compositions and methods in cancer: This invention is in the field of cancer-associated (CA) genes. Specifically it relates to methods for detecting and diagnosing cancer or the likelihood of developing cancer based on the presence or absence of expression of PRDM11 or TBX21 or proteins encoded by those genes. The invention also provides methods and... Agent: Sagres Discovery Inc. Intellectual Property - R440

20070071755 - Novel nucleolar gtpases and method for controlling proliferation of cells: There is provided an isolated polypeptide comprising an amino acid sequence at least 85% homologous to SEQ ID NO: 2 or SEQ ID N: 4, or a conservative variant thereof, wherein the polypeptide regulates proliferation of a cell. There is also provided an isolated polynucleotide encoding the polypeptide of the... Agent: Morgan Lewis & Bockius LLP

20070071763 - Clostridium difficile focussed antibodies: The present invention is concerned with antibodies specific for and which confer immunity against infection by C. difficile or against a vaccine, methods of identifying same, methods of manufacture of medicaments, and methods of treatment of patients using same. Also provided is a method for determining the efficacy of a... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070071764 - Toxin peptide therapeutic agents: and multimers thereof, in which F1 and F2 are half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1; X1, X2, and X3 are each independently -(L)f-P-(L)g-, and f and g are each independently 0 or... Agent: Amgen Inc.

20070071765 - Compositions for immunotherapy and uses thereof: The present invention relates to a method of eliciting a cytotoxic T lymphocyte response to an antigen in an animal, the method comprising pulsing mannose receptor-bearing antigen presenting cells in vitro or ex vivo with a conjugate comprising an antigen and a carbohydrate polymer comprising mannose, wherein said carbohydrate polymer... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070071766 - Compositions comprising fungal immunomodulatory protein and use thereof: This present invention relates to fungal immunomodulatory proteins, compositions and method for use in immunotherapy, treating or preventing cancer due to metastasis or suppression of telomerase activity by down-regulation of the telomerase catalytic subunit (hTERT), activating natural killer cells, macrophage or increasing serum antibody. The present invention also relates to... Agent: Harness, Dickey & Pierce, P.L.C

20070071767 - Tumor antigen: Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises... Agent: Sughrue Mion, PLLC

20070071768 - Use of rip in treating staphylococcus aureus infections: The present composition combines an RNAIII-inhibiting peptide (RIP) with an antimicrobial peptide, such as a cathelicidin, that is capable of binding and neutralizing lipidic and polyanionic components of bacterial cell envelope. In another embodiment, the RIP is combined with an antibiotic, with or without an antimicrobial peptide. The present composition... Agent: Merchant & Gould PC

20070071769 - Recombinant mva virus, and the use thereof: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070071770 - Recombinant mva virus, and the use thereof: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070071771 - Method for limiting the growth of cancer cells using an attenuated measles virus: A method for treating cancer cells is provided comprising directly or systemically administering a therapeutically effective dose of an attenuated measles virus. In one embodiment, the therapeutically effective dose is from about 103 pfus to about 1012 pfus and is delivered by direct injection into a group of cancer cells... Agent: Fish & Richardson P.C.

20070071772 - Treatment of metastatic colon cancer with b-subunit of shiga toxin: The present invention relates to compositions and methods for treating invasive or metastatic cancer, particularly metastatic colon cancer using the B-submit of shiga toxin. The invention further provides methods of identifying compounds usefully for the treatment of invasive or metastatic cancer, particularly metastatic colon cancer.... Agent: Edwards Angell Palmer & Dodge LLP

20070071773 - Compositions and methods for the treatment and prophylaxis of infections caused by gram positive bacteria: The invention relates to methods of treatment, compositions and uses of an isolated and purified peptide for the inhibition of an invasive and/or non-invasive infection of Gram-positive pathogenic bacteria. A specific peptide comprises an amino acid sequence substantially homologous to the amino acid sequence encoded by the SilCR ORF of... Agent: Cooper & Dunham, LLP

20070071774 - Protein d - an igd-binding protein of haemophilus influenzae: A novel surface exposed protein of Haemophilus influenzae or related Haemophilus species is described. The protein named protein D is an Ig receptor for human IgD and has an apparent molecular weight of 42,000. Protein D can be detected in all of 116 encapsulated and non-encapsulated isolates of H. influenzae... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070071775 - Attenuated strains of vibrio cholerae with improved biological safety features in freeze dried form for oral vaccination: The present invention discloses new live attenuated strains for oral immunization against cholera that are provided in freeze dried formulations for long term storage and administration to humans. These strains combine the two most important properties of live attenuated cholera vaccine candidates. One such property is being well tolerated by... Agent: Defillo & Associates, Inc.

20070071776 - Recombinant vaccine against fish infectious diseases: A recombinant vaccine that is useful for immunizing fish against ciliated ectoparasitic protozoans that cause white spot disease also known as ‘ich’. The disease is caused by Ichthyophthirius multifiliis which is a ciliated ectorparasitic protozoan that is an obligate parasite and therefore cannot grow in vitro. The instant vaccine replaces... Agent: Lowe Hauptman Berner, LLP

20070071779 - Compositions for delivering lipophilic agents to the intestinal mucosa and method of making thereof: A composition for delivering lipophilic agents to intestinal mucosa and method of making and use thereof are disclosed. The composition comprises an aqueous solution of one or more short chained C2 to C6 fatty acids, and corresponding salts thereof, and one or more lipophilic agents dissolved in the aqueous solution.... Agent: Advantia Law Group

20070071777 - Oil emulsion for postnatal hormone substitution: The invention relates to a process for the preparation of hormone-containing oil emulsions (lipid emulsions), an isotonic oil emulsion obtainable by such process, and the use of the emulsion according to the invention for the preparation of a medicament for intravenous administration, especially for postnatal hormone substitution in premature babies... Agent: Christie, Parker & Hale, LLP

20070071778 - Stable microemulsion concentrate for delivery of a bioactive biocide/disinfectant/fungicide/fragrance in an aqueous medium providing sustained release: What is described herein is a stable microemulsion concentrate and composition for delivery of an active biocide/disinfectant in an aqueous medium providing sustained release of the active. The composition is effective against both bacteria and fungi.... Agent: Attn: William J. Davis, Esq. International Specialty Products

20070071781 - Compositions for rupturable capsules and methods of making the same: A rupturable capsule that includes a capsule containing a composition is disclosed. Also disclosed are compositions that include silica, oil, a bioorganic filler, colorant, fragrance, and a combination thereof. A method of imparting a colorant, a fragrance, and a combination thereof to an object, that includes rupturing a rupturable capsule... Agent: Michael Best & Friedrich, LLP

20070071780 - Personal care composition comprising a perfume booster accord: A personal care composition comprising a perfume booster accord. The human nose can detect the odor of the perfume booster accord at low concentrations. The perfume booster accord also provides a bigger bloom and longevity of scent. The present invention is further directed to a method of using the personal... Agent: The Procter & Gamble Company Intellectual Property Division

20070071782 - 2-cyanobenzenesulfonamides for combating animal pests: The invention relates to 2-cyanobenzene-sulfonamide compounds of the formula (I) where the variables R1 to R5 are as defined in claim 1 and/or to their agriculturally useful salts. Moreover, the present invention relates to the use of compounds (I) and/or their salts for combating animal pests; agricultural compositions comprising such... Agent: Hutchison Law Group PLLC

20070071783 - Pheromone attractants for the green mirid: A pheromone attractant composition for attracting the green mirid, Creontiades dilutus (St{dot over (a)}l), comprising as the component active in attracting green mirids an effective amount of an admixture of hexyl hexanoate and (E)-2-hexenyl hexanoate.... Agent: Moore & Van Allen PLLC

20070071784 - Organic compounds: The invention is directed at a ready-to-use granule bait composition, its preparation and use for the control of house flies inside houses and animal stalls, fodder stores and sanitary installations.... Agent: Novartis Corporate Intellectual Property

20070071785 - Solid stick insecticidal composition: A solid sick insecticidal composition comprising a base, an insecticide and at least 60 wt % food material. The stick may be used to deposit insecticide composition onto a hard surface for controlling crawling insects.... Agent: Merchant & Gould PC

20070071786 - Wax emulsion compositions for attracting insects and methods of using the same: Attractant compositions suitable for attracting fruit flies are described. The compositions are preferably provided in the form of a wax emulsion of the attractant. Both chemical attractants—such as ammonium acetate and ammonium bicarbonate—and food-based attractants—such as protein and yeasts—are described. Insect lures and traps comprising the disclosed compositions are also... Agent: Jeffer, Mangels, Butler & Marmaro, LLP

20070071789 - Bioactive material delivery systems comprising sol-gel compositions: Implantable medical devices employing a sol-gel composition coatings that functions as a bioactive material reservoir, and the use of sol-gel composition coatings for improved adhesion of organic and inorganic substrates are disclosed.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP Attn: C. Rachal Winger

20070071790 - Biodegradable nanocomposites with enhance mechanical properties for soft tissue: The present invention is directed to a novel poly(diol citrates)-based nanocomposite materials created using completely biodegradable and biocompatible polymers that may be used in tissue engineering. More specifically, the specification describes methods and compositions for making and using nanocomposites comprised of citric acid copolymers and polymers including but not limited... Agent: Marshall, Gerstein & Borun LLP

20070071787 - Composite material comprising a porous semiconductor impregnated with an organic substance: The invention provides a composite material comprising a porous semiconductor impregnated with at least one beneficial organic substance, wherein the beneficial organic substance is present in an amount of at least 15% by weight, based on the weight of the material. Also provided are methods for the preparation of such... Agent: Nixon & Vanderhye, PC

20070071791 - Delivery system for bone growth promoting material: A delivery system that includes a bone growth promoting material encapsulated within a water absorptive gelatinizable covering is used to promote bone growth in order to repair a bone defect and/or strengthen a weakened bone region. The delivery system may be shaped and sized in order to fit within a... Agent: Workman Nydegger (f/k/a Workman Nydegger & Seeley)

20070071788 - Skin integrated device: A skin integrated device for implantation with an improved device-skin interface for the ingrowths of skin cells and tissues throughout the pores, having a solid frame, which may also be permeable. The characteristics of pore size, porosity and size of the compressed and sintered particles constitute a long-term skin integrated... Agent: Mark Pitkin

20070071792 - In vivo formed matrices including natural biodegradale polysaccharides and ophthalmic uses thereof: In vivo formed matrices including natural biodegradable polysaccharides are described. The matrix is formed from a plurality of natural biodegradable polysaccharides having pendent coupling groups. The matrix can also include a bioactive agent that can be released to provide a therapeutic effect to a patient. The formed matrices are particularly... Agent: Kagan Binder, PLLC

20070071793 - Cure for prostate enlargement frequency of urination and cancer: This is a chemical compound designed to eradicate cancer from the prostate (and possibly other parts of the body) restore the prostate to it's normal size, cure frequency of urination and restore urination back to it's youthful state.... Agent: Leon Clark

20070071794 - Drugs for treating diabetes: The present invention provides an agent for recovering insulin secretion function which contains at least one of the amino acids selected from the group consisting of aspartic acid, cystine, serine, asparagine, isoleucine, histidine, hydroxyproline, glutamic acid, valine and salts thereof as an active ingredient; a functional food which contains the... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070071795 - Antibodies as growth promoting agents: Animal feed is supplemented with antibody-containing egg powder as a means of improving growth of animals.... Agent: Ade & Company Inc.

20070071796 - Administration form based on cross-linked hydrophilic polymers: The invention relates to a film-shaped administration form for surface administration of at least one active ingredient and/or foodstuff to a living thing. Said administration form comprises at least one layer containing an active ingredient and/or foodstuff, said layer being based on cross-linked hydrophilic polymers and containing 20 wt.-% glycerine... Agent: Frommer Lawrence & Haug

20070071797 - Lotioned fibrous structures: Lotioned fibrous structures and sanitary tissue products comprising such fibrous structures are provided. More particularly, fibrous structures comprising two or more different compositions arranged on a surface of the fibrous structure such that one of the compositions is sandwiched between the fibrous structure surface and the other composition is provided.... Agent: The Procter & Gamble Company Intellectual Property Division

20070071798 - Perforated bioabsorbable oil film and methods for making the same: A bio-absorbable stand-alone film is derived at least in part from fatty acids. The bio-absorbable stand-alone film can have anti-adhesive, anti-inflammatory, non-inflammatory, and wound healing properties, and can additionally include one or more therapeutic agents incorporated therein. The stand-alone film has one or more perforations or depressions formed therein. Corresponding... Agent: Lahive & Cockfield, LLP

20070071800 - Acrylic pressure sensitive adhesives: Solution acrylic polymers suitable for dispersing drugs are particularly useful in transdermal drug delivery applications.... Agent: National Starch And Chemical Company

20070071799 - Anchor point for affixing tubes and the like to skin: An Anchor Point is presented for anchoring a tube or the like to the body. The anchors are long lasting and improve patient mobility. In one embodiment the Anchor Point consists of two identical self adhesive flat components. At the proximal end, each Anchor Point component has an interrupted patch... Agent: Chris Tacklind

20070071803 - Dermal penetration enhancers and drug delivery systems involving same: The invention relates to a method for treatment or prophylaxis of a disease or condition in an animal comprising administering to a mucosal membrane of said animal in need of such treatment a therapeutically effective amount of a drug delivery system comprising at least one physiologically active agent or prodrug... Agent: Foley And Lardner LLP Suite 500

20070071801 - Patch for treating symptoms of a skin abscess: A patch, or bandage for treating skin infections has a backing with pressure-sensitive adhesive for securing on a user's skin in the area of the boil. A liquid absorbent member is positioned in the center of the patch, while a carrier with a medicinal formulation, comprising a menthol solution, surrounds... Agent: Keaty Professional Law Corporation Thomas S. Keaty

20070071802 - Topical anesthetic for dental procedures: A topical anesthetic for dental procedures is provided containing about 3 wt % to 10 wt % tetracaine in a vehicle suitable for administration to the oral mucosa. The vehicle for transporting the tetracaine includes a water soluble mucoadhesive or a combination of mucoadhesives such as a high molecular weight... Agent: Grace J Fishel

20070071804 - Compositions and methods of preparation of liposomal microparticulate il-12: This invention provides methods and compositions for localized delivery of IL-12 to a desired site. The composition comprises liposomes carrying IL-12. The liposomes comprise phosphatidyl choline, phosphatidyl glycerol and cholesterol. The size and composition of the liposomes is such that there is minimal leakage into the systemic circulation. These compositions... Agent: Hodgson Russ LLP

20070071805 - Treatment of inflammation and vascular abnormalities of the eye: Inflammation and vascular abnormalities of the eye, including those related to ischemia, its prophylaxis and its alleviation, are treated by administration to the mammal of small amounts of phosphate-glycerol group presenting bodies such as phosphatidylglycerol liposomes.... Agent: Foley & Lardner LLP

20070071808 - Capsule filled with honey: Capsules containing honey or other sweeteners that may be added to beverages are described. The capsules may be made from a material that dissolves in water or other fluids, or, alternatively, the capsule may be remain intact in a fluid and provide an edible capsule sweetener. The capsule may contain... Agent: Mccarter & English LLP Cityplace I

20070071807 - Capsule-type drug-releasing device and capsule-type drug-releasing device system: A capsule-type drug-releasing device is capable of freely controlling the release and stoppage of a drug and causing neither the back flow of contents of a stomach, an intestine, or the like nor clogging with the contents. A capsule-type drug-releasing device may include: a capsule-shaped casing; a cation exchange membrane... Agent: Seed Intellectual Property Law Group PLLC

20070071806 - Tansmucosal drug delivery system: Disclosed are preparations and formulations of high thermodynamic activity lipophilic associations (LA), in which there is pairing between an ionizable pharmaceutical agent and a lipophilic species having ionic characteristics opposite to that of the pharmaceutical agent. Such lipophilic associations manifest high thermodynamic activity, as evidenced by their being predominantly in... Agent: Viksnins Harris & Padys Pllp

20070071809 - Ginger containing compositions to control pain: Pain is controlled by ingesting a composition comprising at least about 510 mg of ginger, at least about 1000 mg of glucosamine and at least about 1200 mg of chondroitin sulfate or methylsulfonylmethane, all weights based on a total daily dosage of the composition.... Agent: Whyte Hirschboeck Dudek S C

20070071810 - Additive for tablets: A disintegrant for tablets consisting of an α-1,4-glucan having a degree of polymerization of not less than 180 and less than 1230 and a dispersity (weight average molecular weight “Mw”/number average molecular weight “Mn”) of not more than 1.25 or a modified product thereof. A binder for tablets consisting of... Agent: Mark D. Saralino (general) Renner, Otto, Boisselle & Sklar, LLP

20070071813 - Novel dosage formulation: wherein the definitions are described in claim 1, or pharmaceutically acceptable acid addition salts thereof and a water soluble poloxamer in which the compound of formula I and the water soluble poloxamer are processed by hot melt extrusion, and then the hot melt extrudate is mixed with other ingredients to... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070071815 - Oral formulation of creatine derivatives and method of manufacturing same: Oral formulation of creatine derivative and in particular creatine esters and more particularly ethyl esters of creatine are described. The formulations comprise a phosphate such as dicalcium phosphate, a biodegradable polymer such as a polyvinyl pyrrolidine and a starch. The formulation may further comprise other excipients such as metal salt... Agent: Bozicevic, Field & Francis LLP

20070071812 - Pharmaceutical composition containing fenofibrate and method for the preparation thereof: The invention concerns a pharmaceutical composition containing micronized fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose. The cellulose derivative represents less than 20 wt. % of the composition. The association of micronized fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enables... Agent: Buchanan, Ingersoll & Rooney PC

20070071811 - Stable combinations of amlodipine besylate and benazepril hydrochloride: The present invention provides a pharmaceutical composition comprising benazepril and amlodipine wherein the benazepril and the amlodipine are in physical contact with one another, and methods for making the same.... Agent: Kenyon & Kenyon LLP

20070071814 - Vaginal tablets comprising misoprostol and methods of making and using the same: The present invention is directed to vaginal tablets comprising misoprostol and a pharmaceutically acceptable pH insensitive, hydrophilic cellulose material, wherein the vaginal tablets do not contain a hydrophobic release controlling agent, and wherein the misoprostol and the pharmaceutically acceptable pH insensitive, hydrophilic cellulose material are in a ratio of about... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070071818 - Effervescent formulations comprising apomorphine: An effervescent formulation comprising apomorphine, preferably comprising multilayer effervescent microspheres containing an acidic substance, a basic substance and water-soluble isolating agent. An effervescent formulation comprising apomorphine wherein dissolution in water of the multilayer effervescent microspheres leads, after almost immediate effervescence, to a solution or a homogeneous dispersion of the apomorphine.... Agent: Nixon Peabody LLP - Patent Group

20070071817 - Effervescent oral care compositions and method of use: Solid effervescent compositions are described. The solid compositions include an edible acid and a carbonate salt (e.g., sodium carbonate or sodium bicarbonate). The compositions can further include one or more water soluble functional ingredients. The solid compositions can be free of insoluble particulate material so as to prevent damage to... Agent: Merchant & Gould PC

20070071816 - Oral drug delivery system: An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a composition selected from... Agent: Sughrue Mion, PLLC

20070071819 - Multiple unit modified release compositions of carbamazepine and process for their preparation: The present invention relates to multiple-unit modified release carbamazepine compositions for oral administration which include: (i) at least one extended release unit, and (ii) at least one enteric release unit. Also provided are processes for the preparation of multiple-unit modified release compositions of carbamazepine.... Agent: Ranbaxy Inc.

20070071820 - Delayed release pharmaceutical formulations: Delivery of a drug is controlled to impart a delay before release after administration by formulating the drug with a disruption agent to provide a core, and coating the core with a regulatory membrane comprising a water-soluble gel-forming polymer and a water-insoluble film-forming polymer.... Agent: Duane Morris LLP Patent Department

20070071822 - Film coated tablet for improved upper gastrointestinal tract safety: A novel oral dosage to be delivered to the stomach comprising a safe and effective amount of an active ingredient selected from the group consisting of emepronium bromidebromide, doxycycline, and other tetracyclines/antibiotics, iron preparations, quinidine, nonsteroidal anti-inflammatory drugs, alprenolol, ascorbic acid, captopril, theophylline, zidovoudine (AZT), bisphosphonates and mixtures thereof and... Agent: The Procter & Gamble Company Intellectual Property Division

20070071821 - Formulation for providing an enteric coating material: The present invention relates to an enteric coating formulation, as well as methods for preparing and using said enteric coating formulation. In particular, the invention relates to an enteric coating formulation that is made up of foodeous approved materials.... Agent: Fleshner & Kim, LLP

20070071823 - Polyampholytes for delivering polyions to a cell: An polyampholyte is utilized in a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The complex can be formed with an appropriate amount of positive and/or negative charge such that the resulting complex can be delivered to the extravascular space and may be further delivered to... Agent: Mirus Corporation

20070071824 - Treatment of mucositis using n-acetylcysteine: This present invention provides a therapeutic composition for use in the treatment of mucositis and a method for using such a therapeutic composition. The therapeutic composition includes a pharmaceutical substance effective for treating mucositis formulated with a biocompatible polymer, such as a biocompatible reverse-thermal gelation polymer.... Agent: Marsh, Fischmann & Breyfogle LLP

20070071825 - Device and method for making particles: Device for continuously producing particles, consisting of a homogenising compartment (1) including at least one inlet (2) for feeding in an organic phase, an inlet (3) for feeding in an aqueous phase, a mixing system (4) and an outlet (5).... Agent: Nixon & Vanderhye, PC

20070071826 - Method for preparing nano-scale or amorphous particle using solid fat as a solvent: The present invention relates to a method for preparing nanoscale or amorphous particles using solid fat as a solvent. According to the present invention, nanoscale or amorphous particles of active ingredients are prepared by using fat as a solvent, wherein the fat is in solid phase at room temperature. The... Agent: Sheridan Ross PC

20070071827 - Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein: Compositions for stimulating the immune system and for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include immunogenic epitopes of the HER-2 proteins and chimeric and multivalent peptides which comprise such epitopes. The present invention also relates to polynucleotides which encode the chimeric peptides. Also... Agent: Calfee Halter & Griswold, LLP

20070071828 - Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from... Agent: Wilson Sonsini Goodrich & Rosati

20070071829 - Universally applicable virus inactivated blood plasma produced from portions of non-caucasian plasma: A blood plasma for human use pooled from donors which belong to 10% or more to a non-Caucasian population, the plasma obtainable by mixing blood or blood plasma of blood groups A and B, optionally AB without admixing substantial amounts of blood or blood plasma of blood group 0 characterized... Agent: Jacobson Holman PLLC

20070071830 - Method for increasing bioavailability of lipophilic bioactive compounds: A primary composition that includes at least one lipophilic bioactive compound and a whey protein in an amount effective to increase the bioavailability of the lipophilic bioactive compound, and methods of forming the same. Also, an oral composition that contains the primary composition in a foodstuff, in a food supplement,... Agent: Bell, Boyd & Lloyd LLP

20070071831 - Product for the prevention and the treatment of grapevine infections and method of preparation thereof: A product is described for the prevention and/or treatment of grapevine infections, obtained by the partial or total neutralization of lees originating from winemaking processes, for example by means of alkali or alkali-earth metal oxides or hydroxides; such product generally has a pH comprised between 6.0 and 8.0 and a... Agent: Lucas & Mercanti, LLP

20070071832 - Method for cleaning a lumen: A method and apparatus for removing soil from an inner surface of a lumen wall of a medical instrument are disclosed. A carrier gas entrains particles capable of sublimation at room temperature and transports the particles into and through the lumen. As the particles collide with the soil attached to... Agent: Kusner & Jaffe Highland Place Suite 310

20070071833 - Fungicidal mixtures for controlling rice pathogens: m

20070071835 - Administering pharmaceutical compositions to the mammalian central nervous system: Methods, compositions and systems are provided for the non-invasive transnasal and transocular drug delivery to the central nervous system using eriodictyon fluid extract technology. By administration through the olfactory nerve or the optical nerve, the delivery of a biologically active substance of interest into the CNS and CSF can be... Agent: Morgan, Lewis & Bockius LLP (sf)

20070071834 - Traditional chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method: The present invention discloses a traditional Chinese medicine preparation for cardio-cerebral blood vessel diseases, it is prepared through extracting danshen and Notoginseng by lye, precipitating with alcohol, concentrating, and adding other medicine and excipients. Then using the HAPLY-MS and HAPLY fingerprint Atlas to characterize its Physicochemical properties completely. Using the... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070071836 - Transfer factor preparations and associated methods: A drink includes an edible liquid or semisolid preparation and transfer factor. The drink may also include lactoferrin and one or more preservatives. An edible preparation includes a fruit component and transfer factor. The fruit component may include at least one oligoproanthocyanidin-containing fruit. The edible preparation may also include lactoferrin.... Agent: Trask Britt

20070071837 - Treatment of aspirin resistance with radix salviae mitiorhizae, its extract and composition: The present invention relates to the treatment of aspirin resistant cardio-cerebrovascular diseases using RSM (RSM), its extract and composition comprising any or both of them, especially the formulation Dan Shen Drop Pills (Drop Pills of RSM).... Agent: Harness, Dickey & Pierce, P.L.C

20070071838 - Method for the treatment of cachexia: A pharmaceutically acceptable salt of perindopril of formula (I) is made from a protected precursor compound of formula (II) wherein R represents a carboxyl protecting group, which process comprises subjecting a compound of formula (II) to deprotection of the carboxylic group COOR attached to the heterocyclic ring so as to... Agent: Knoble, Yoshida & Dunleavy

20070071839 - Compositions for the treatment of atopic dermatitis, skin allergic conditions and acne: The present invention relates to topical compositions containing: a) Ginkgo biloba terpenes; b) floroglucinols pure or in mixture thereof, extracted from Humulus lupulus, Hypericum sp and Mirtus sp; c) Zanthoxylum bungeanum or Echinacea angustifolia lipophilic extract; for the treatment of atopic dermatitis, skin allergic conditions and acne.... Agent: Young & Thompson

20070071840 - Method for treatment of cartilage disorders with centella extract: The invention is a method for the treatment of mammalian articular cartilage disorders, inflammatory joint disease, trauma-related cartilage injuries, and degenerative disc disease. The method involves treating the affected area with a composition containing a therapeutically effective dose of Centella extract. The composition is delivered locally by parenteral administration to... Agent: Philip S. Johnson Johnson & Johnson

20070071841 - Method for lowering blood pressure in pre-hypertensive individuals and/or individuals with metabolic syndrome: The present invention relates to a method of preventing and/or treating Metabolic Syndrome and/or the conditions that comprise Metabolic Syndrome by administering to a mammal, including a human, a dietary supplement comprising grape extract. This invention also relates to a method of treating and/or preventing pre-hypertension by administering to a... Agent: Kenyon & Kenyon LLP

20070065359 - Nanocells for diagnosis and treatment of diseases and disorders: The present invention relates to novel nanocell compositions and their use in imaging, diagnostic and treatment methods. In one embodiment, nanocells tailored for imaging methods comprise a nanocore surrounded by a lipid matrix, and are modified to contain a radionuclide core or a nanocore with an emission spectra. The nanocells... Agent: Ronald I. Eisenstein Nixon Peabody LLP

20070065360 - Nonpolar thymidine analogs: e

20070065361 - Ligands to radiation-induced molecules: A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. In some embodiments, the method includes the steps of (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070065362 - Gastrin receptor-avid peptide conjugates: A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject... Agent: Kohn & Associates PLLC

20070065363 - Quantifying hemodynamic response to drug therapy using implantable sensor: Systems and methods provide for assessing a patient's hemodynamic response to a drug therapy. A patient's hemodynamic response to a drug therapy is monitored using sensor data acquired using one or more sensors. The patient's hemodynamic response to the drug therapy is quantified, such as by quantifying a patient's sensitivity... Agent: Hollingsworth & Funk, LLC

20070065365 - Abuse-resistant transdermal system: An abuse-resistant transdermal system which contains, in addition to one or more active ingredients with potential for abuse, at least one gel-forming agent in quantities such that it forms a gel with a minimum quantity of an aqueous liquid, and contains as further agents which complicate or prevent abuse at... Agent: Crowell & Moring LLP Intellectual Property Group

20070065364 - Tamper resistant dosage form comprising co-extruded, sequestered adverse agent particles and process of making same: The present invention relates to co-extruded pharmaceutical compositions and dosage forms comprising an adverse agent, such as an opioid antagonist, which can be sequestered. The pharmaceutical compositions and dosage forms diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to... Agent: Duane Morris LLP Patent Department

20070065366 - Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation: The invention relates to a liquid, propellant-free pharmaceutical formulation in the form of ready-to-use preparation for administration by nebulisation comprising a water soluble salt of the beta2-agonist 8-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone as active ingredient. The active ingredient is chemically stable in the formulation, and said formulation is provided of an adequate shelf-life suitable... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070065368 - Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation: The present invention relates to the ability of SAP to suppress fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress fibrocytes. Methods and compositions for suppressing fibrocytes using these proteins are provided. These methods are useful in a variety of applications including... Agent: Michelle Lecointe Baker Botts L.L.P.

20070065367 - Method of treating pulmonary disease with interferons: A method of treating a pulmonary disease such as, for instance idiophathic pulmonary fibrosis (IPF) and asthma, comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided.... Agent: Klauber & Jackson

20070065369 - Novel methods and composition for delivering macromolecules to or via the respiratory tract: A composition comprises a lipid-based microstructure with at least one bioactive macromolecule. The composition provides improved bioavailability and is capable of rapidly releasing a bioactive macromolecule. It is believed that the improved bioavailability is due, at least in part, to the reduction of scavenging by bronchoalveolar macrophages and/or mucociliary clearance.... Agent: Nektar Therapeutics

20070065370 - Suspension aerosol formulationis of pharmaceutical products: Pharmaceutical preparations for producing powder aerosols using propellant gases which use TG 227, and possibly also TG 11, TG 12, TGH 114, propane, butane, pentane or DME.... Agent: Micha